FDA clears orforglipron, GLP-1 pill without restrictions

The U.S. Food and Drug Administration approved Eli Lilly’s Foundayo, the oral GLP-1 drug orforglipron, on April 1 for adults with obesity or adults who are overweight and have at least one weight-related medical condition. The approval gives Lilly a once-daily weight-loss pill that can be taken without food or water restrictions, according to the FDA-approved label and Lilly’s announcement. The drug is approved for use with a reduced-calorie diet and increased physical activity. Lilly said prescriptions were accepted immediately and shipping through LillyDirect began April 6. ### What exactly did the FDA approve? Foundayo was approved for long-term weight reduction in adults with obesity, or adults with overweight who also have at least one weight-related comorbid condition, the FDA approval letter said. The agency’s novel drug approvals page lists Foundayo, orforglipron, as approved on April 1, 2026. (fda.gov) The label says Foundayo is a GLP-1 receptor agonist tablet taken orally once daily. The prescribing information says patients should start at 0.8 mg once daily, increase to 2.5 mg after at least 30 days, then to 5.5 mg after another 30 days, with optional increases up to a maximum 17.2 mg based on response and tolerability. (accessdata.fda.gov) ### Why is the pill’s dosing drawing attention? The FDA label says Foundayo can be taken orally once daily “with or without food.” Lilly said in its release that the pill can be taken at any time of day without food or water restrictions. FDA officials also described it as a tablet that does not need to be taken on an empty stomach. (accessdata.fda.gov) Acting Center for Drug Evaluation and Research Director Tracy Beth Høeg said in the FDA release that the approval gives patients “an additional option” in the form of a GLP-1 pill that does not need to be taken on an empty stomach. Deborah Horn, director of the Center for Obesity Medicine at McGovern Medical School at UTHealth Houston, said in Lilly’s release that a once-daily pill with no food or water restrictions could offer patients more flexibility. (accessdata.fda.gov) ### How fast did the FDA review it? The FDA said the decision was issued 50 days after filing and 294 days before the application’s PDUFA date of January 20, 2027. The agency said Foundayo was the fifth approval under the Commissioner’s National Priority Voucher pilot program and the first new molecular entity approved under that program. (fda.gov) FDA Commissioner Martin Makary said the approval showed what the agency could do by “eliminat[ing] delays” and maintaining constant communication with the company during review. The FDA said the pilot program, launched in 2025, is designed to speed applications that address what it calls critical national health priorities. (fda.gov) ### What do the trial results show? Lilly said adults taking the highest dose in the ATTAIN-1 trial lost an average of 27.3 pounds, or 12.4% of body weight, among those who stayed on treatment. Across all participants regardless of trial completion, Lilly said the average weight loss at the highest dose was 25 pounds, or 11.1%, versus 5.3 pounds, or 2.1%, with placebo. (fda.gov) Lilly also said the ATTAIN program showed reductions in waist circumference, non-HDL cholesterol, triglycerides and systolic blood pressure across doses. Those statements came from the company’s release; the FDA announcement focused on the approval decision and dosing information rather than detailed efficacy tables. (investor.lilly.com) ### What warnings and limits come with the approval? The FDA-approved label carries a boxed warning on risk of thyroid C-cell tumors. The prescribing information says Foundayo is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or in patients with Multiple Endocrine Neoplasia syndrome type 2. (investor.lilly.com) The label also says concomitant use with another GLP-1 receptor agonist is not recommended, and it warns about acute pancreatitis. Tablets should be swallowed whole and not broken, crushed or chewed, according to the prescribing information. ### Where does Lilly go from here? (accessdata.fda.gov) Lilly said on April 1 that Foundayo would be available through LillyDirect, U.S. retail pharmacies and telehealth providers, with shipping starting April 6. A separate Lilly update on April 9 said the drug was then available and shipping to retail pharmacies nationwide, with commercial coverage starting at $25 per month and self-pay pricing at $149 per month through Lilly’s channels. (accessdata.fda.gov) (investor.lilly.com)